Emily I Chen
Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, USA
Posters & Accepted Abstracts: J Cancer Sci Ther
Major advances in early detection and therapy have significantly increased the survival of breast cancer patients. Unfortunately, most cancer therapies are known to carry a substantial risk of adverse long-term treatment-related effects such as chemotherapy-induced peripheral neuropathy (CIPN). Little is known about patient susceptibility to severe side effects after chemotherapy. Thus, for those at high risk for disease recurrence, a major concern is the patient├ó┬?┬?s inability to tolerate the full dose/duration of therapy to improve outcome. Recent advances in proteomic technologies incorporating mass spectrometry (MS) for biomarker discovery show great promise to provide clinically relevant protein biomarkers. In this study, we evaluated the association between protein content in serum exosomes and severity of CIPN. Women with early stage breast cancer receiving adjuvant taxane chemotherapy were assessed with the FACT-Ntx score and serum was collected before and after the taxane treatment. Based on the change in FACT-Ntx score from baseline to 12 month follow-up, we separated patients into two groups: those who had no change (Group 1) and those who had a >20% worsening (Group 2). MS-based proteomics technology was used to identify proteins present in serum exosomes to determine potential biomarkers. Statistical analysis revealed a 12-protein signature that resulted in a distinct separation between baseline serum samples of both groups (FDR<0.2) suggesting that the baseline samples can predict subsequent neurotoxicity. Since we found more distinct exosomal proteins at baseline between these two groups of patients we speculate that there are host-factors that could predispose patients to this toxicity.
Cancer Science & Therapy received 3644 citations as per Google Scholar report